Search results

capecitabine (Xeloda)

In combination with oxaliplatin for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.

Capecitabine (Xeloda®)

Metastatic breast cancer

Capecitabine 150 and 500mg tablets (Xeloda®)

Following surgery for Stage III (Dukes C stage) colon cancer

capecitabine 150mg and 500mg tablets (Xeloda)

first line treatment of patients with advanced gastric cancer in combination with a platinum-based chemotherapy regimen

capecitabine (Xeloda)

Metastatic colorectal cancer

bevacizumab (Avastin)

bevacizumab in combination with capecitabine is indicated for first-line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate.

tucatinib (Tukysa)

In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens

trastuzumab (Herceptin)

in combination with capecitabine or fluorouracil and cisplatin for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. It is indicated for use only in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, as determined by an accurate and validated assay.

lapatinib (Tyverb)

Advanced or metastatic breast cancer

lapatinib (Tyverb)

For the treatment of patients with advanced or metastatic breast cancer

eribulin (Halaven)

For the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.

elacestrant (Korserdu)

For the treatment of postmenopausal women, and men, with oestrogen receptor-positive (ER+), human epidermal factor receptor 2-negative (HER2-), locally advanced or metastatic (m) breast cancer (BC) with an activating oestrogen receptor 1 (ESR1) mutation (mut) who have disease progression following at least one line of endocrine therapy (ET) including a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).